CD274 and non-small cell lung carcinoma: Moreover, the persistence of PD-L1 expression or the PD-L1 positive CTCs after anti-PD-L1 therapy in non-small cell lung cancer (NSCLC) patients correlated with progressive disease, suggestive of an escape mechanism to check point therapy (166).